246 related articles for article (PubMed ID: 28216662)
1. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway.
Du C; Li DQ; Li N; Chen L; Li SS; Yang Y; Hou MX; Xie MJ; Zheng ZD
Sci Rep; 2017 Feb; 7():42876. PubMed ID: 28216662
[TBL] [Abstract][Full Text] [Related]
2. miR-5590-3p inhibited tumor growth in gastric cancer by targeting DDX5/AKT/m-TOR pathway.
Wu N; Han Y; Liu H; Jiang M; Chu Y; Cao J; Lin J; Liu Y; Xu B; Xie X
Biochem Biophys Res Commun; 2018 Sep; 503(3):1491-1497. PubMed ID: 30029874
[TBL] [Abstract][Full Text] [Related]
3. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
[TBL] [Abstract][Full Text] [Related]
4. DDX21 promotes gastric cancer proliferation by regulating cell cycle.
Cao J; Wu N; Han Y; Hou Q; Zhao Y; Pan Y; Xie X; Chen F
Biochem Biophys Res Commun; 2018 Nov; 505(4):1189-1194. PubMed ID: 30322617
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.
Taniguchi T; Iizumi Y; Watanabe M; Masuda M; Morita M; Aono Y; Toriyama S; Oishi M; Goi W; Sakai T
Cell Death Dis; 2016 May; 7(5):e2211. PubMed ID: 27148684
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA MIAT promotes gastric cancer growth and metastasis through regulation of miR-141/DDX5 pathway.
Sha M; Lin M; Wang J; Ye J; Xu J; Xu N; Huang J
J Exp Clin Cancer Res; 2018 Mar; 37(1):58. PubMed ID: 29540201
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcylation promotes colorectal cancer progression by regulating protein stability and potential catcinogenic function of DDX5.
Wu N; Jiang M; Han Y; Liu H; Chu Y; Liu H; Cao J; Hou Q; Zhao Y; Xu B; Xie X
J Cell Mol Med; 2019 Feb; 23(2):1354-1362. PubMed ID: 30484950
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of DDX5 Inhibits the Proliferation and Tumorigenesis in Esophageal Cancer.
Ma Z; Feng J; Guo Y; Kong R; Ma Y; Sun L; Yang X; Zhou B; Li S; Zhang W; Jiang J; Zhang J; Qiao Z; Cheng Y; Zha D; Liu S
Oncol Res; 2017 Jul; 25(6):887-895. PubMed ID: 28244855
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-224 aggrevates tumor growth and progression by targeting mTOR in gastric cancer.
Zhang Y; Li CF; Ma LJ; Ding M; Zhang B
Int J Oncol; 2016 Sep; 49(3):1068-80. PubMed ID: 27315344
[TBL] [Abstract][Full Text] [Related]
10. Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway.
Li Z; Li Y; Jia Y; Ding B; Yu J
Arch Biochem Biophys; 2020 May; 685():108352. PubMed ID: 32240637
[TBL] [Abstract][Full Text] [Related]
11. DDX5 Silencing Suppresses the Migration of Basal cell Carcinoma Cells by Downregulating JAK2/STAT3 Pathway.
Quan Z; Zhang BB; Yin F; Du J; Zhi YT; Xu J; Song N
Technol Cancer Res Treat; 2019; 18():1533033819892258. PubMed ID: 31870221
[TBL] [Abstract][Full Text] [Related]
12. DDX5 promotes hepatocellular carcinoma tumorigenesis via Akt signaling pathway.
Xue Y; Jia X; Li L; Dong X; Ling J; Yuan J; Li Q
Biochem Biophys Res Commun; 2018 Sep; 503(4):2885-2891. PubMed ID: 30119889
[TBL] [Abstract][Full Text] [Related]
13. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
[TBL] [Abstract][Full Text] [Related]
14. ESCO2 knockdown inhibits cell proliferation and induces apoptosis in human gastric cancer cells.
Chen H; Zhang L; He W; Liu T; Zhao Y; Chen H; Li Y
Biochem Biophys Res Commun; 2018 Feb; 496(2):475-481. PubMed ID: 29330052
[TBL] [Abstract][Full Text] [Related]
15. PPP2R2D, a regulatory subunit of protein phosphatase 2A, promotes gastric cancer growth and metastasis via mechanistic target of rapamycin activation.
Yu S; Li L; Wu Q; Dou N; Li Y; Gao Y
Int J Oncol; 2018 Jun; 52(6):2011-2020. PubMed ID: 29568966
[TBL] [Abstract][Full Text] [Related]
16. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer.
Du W; Wang S; Zhou Q; Li X; Chu J; Chang Z; Tao Q; Ng EK; Fang J; Sung JJ; Yu J
Oncogene; 2013 Jul; 32(28):3319-28. PubMed ID: 22907434
[TBL] [Abstract][Full Text] [Related]
17. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
Lang SA; Gaumann A; Koehl GE; Seidel U; Bataille F; Klein D; Ellis LM; Bolder U; Hofstaedter F; Schlitt HJ; Geissler EK; Stoeltzing O
Int J Cancer; 2007 Apr; 120(8):1803-10. PubMed ID: 17230506
[TBL] [Abstract][Full Text] [Related]
18. Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling.
Dou N; Yu S; Ye X; Yang D; Li Y; Gao Y
Oncotarget; 2016 Dec; 7(52):86161-86173. PubMed ID: 27863387
[TBL] [Abstract][Full Text] [Related]
19. The role of miR-18a in gastric cancer angiogenesis.
Zheng Y; Li S; Ding Y; Wang Q; Luo H; Shi Q; Hao Z; Xiao G; Tong S
Hepatogastroenterology; 2013 Oct; 60(127):1809-13. PubMed ID: 24624454
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid 2-hydroxylation inhibits tumor growth and increases sensitivity to cisplatin in gastric cancer.
Yao Y; Yang X; Sun L; Sun S; Huang X; Zhou D; Li T; Zhang W; Abumrad NA; Zhu X; He S; Su X
EBioMedicine; 2019 Mar; 41():256-267. PubMed ID: 30738828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
